Achillion Pharmaceuticals (ACHN) Earns News Impact Score of 0.19

Media stories about Achillion Pharmaceuticals (NASDAQ:ACHN) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.8219384873181 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the media stories that may have impacted Accern’s rankings:

How to Become a New Pot Stock Millionaire

ACHN remained flat at $$3.49 on Friday. 1,057,497 shares of the company’s stock traded hands, compared to its average volume of 1,926,989. Achillion Pharmaceuticals has a one year low of $2.58 and a one year high of $5.66. The firm has a market capitalization of $481.25, a price-to-earnings ratio of -5.63 and a beta of 0.89.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.01). During the same period in the prior year, the business posted ($0.03) EPS. analysts expect that Achillion Pharmaceuticals will post -0.55 EPS for the current fiscal year.

Several brokerages have weighed in on ACHN. BidaskClub lowered shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 27th. B. Riley began coverage on shares of Achillion Pharmaceuticals in a research report on Thursday, February 8th. They set a “neutral” rating and a $3.50 target price on the stock. Finally, Leerink Swann restated a “buy” rating and set a $5.00 target price on shares of Achillion Pharmaceuticals in a research report on Monday, December 11th. One analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. Achillion Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $4.89.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3338893/achillion-pharmaceuticals-achn-earns-news-impact-score-of-0-19.html.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Insider Buying and Selling by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

State Street  Lifted to Buy at Deutsche Bank
State Street Lifted to Buy at Deutsche Bank
TriNet  Scheduled to Post Quarterly Earnings on Monday
TriNet Scheduled to Post Quarterly Earnings on Monday
Op Bancorp  Now Covered by Keefe, Bruyette & Woods
Op Bancorp Now Covered by Keefe, Bruyette & Woods
UBS Upgrades MGM Resorts International  to Positive
UBS Upgrades MGM Resorts International to Positive
Arconic  Lowered to “Neutral” at Longbow Research
Arconic Lowered to “Neutral” at Longbow Research
Umpqua  – Analysts’ Recent Ratings Changes
Umpqua – Analysts’ Recent Ratings Changes


© 2006-2018 Ticker Report. Google+.